1. The Effects of Treatment on Peripheral Blood Immune Cell Profile in Pancreatic Ductal Adenocarcinoma (PDAC)
- Author
-
SKAISTE TULYTE, DAINIUS CHARACIEJUS, REDA MATUZEVICIENE, AUSRA JANIULIONIENE, MANTAS RADZEVICIUS, TADAS ZVIRBLIS, and AUDRIUS SILEIKIS
- Subjects
Killer Cells, Natural ,Pancreatic Neoplasms ,Cancer Research ,Oncology ,T-Lymphocyte Subsets ,Humans ,General Medicine ,Carcinoma, Pancreatic Ductal - Abstract
This study evaluated whether circulating lymphocytes, assessed by flow cytometry, is a prognostic biomarker in pancreatic ductal adenocarcinoma (PDAC).We studied T cell subsets in blood samples from a cohort of 41 patients diagnosed with PDAC. Patients underwent surgery of the primary site and adjuvant chemotherapy or were treated with 1A decline in CD19+ B lymphocytes, natural killer (NK) cells CD3-CD56+CD16+, and T regulatory cells CD4+FOXP3+ during treatment was observed. NKT-like cells CD3+CD56+ and cytotoxic T cells CD3+CD8+ tended to increase after two months and decrease after that.Statistically significant changes in lymphocyte counts in peripheral blood were detected in patients with PDAC during treatment. more...
- Published
- 2022
- Full Text
- View/download PDF